2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

By Rishika Sadam Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...

By Rishika Sadam and Kashish Tandon Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a ...